Global Companion Diagnostics for Oncology Market Research Report—Forecast till 2027

$4,450$6,250

Global Companion Diagnostics for Oncology Market is expected to witness a substantial market expansion at a CAGR of 22.57% during the review period of 2020 to 2027.

Clear

Description

Global Companion Diagnostics for Oncology Market Research Report—Forecast till 2027

Market Synopsis
Global Companion Diagnostics for Oncology Market is expected to witness a substantial market expansion at a CAGR of 22.57% during the review period of 2020 to 2027. The global market growth is attributed to rising R&D and drug-diagnostic co-development, increasing preference for personalized medicine, the growing global incidence of cancer, and rising product approvals by major players.
The global companion diagnostics for oncology market owing to the highest market value of USD 1,603.16 Million in 2019. Major market players are focusing on various growth strategies such as product launches, product expansion, and business expansions to serve the increasing demand for personalized medicine. These product launches and business expansion are expected to set the growth of the companion diagnostics for the oncology market during the review period. However, the lack of reimbursement in developing regions is expected to restrain the market growth during the review period.
Market Segmentation
Global Companion Diagnostics for Oncology Market has been classified into Products & Services, Technology, Indication, and End User.
Based on product & service, has been classified into assays, kits & reagents, and software & services.
In terms of technology type, the global companion diagnostics for the oncology market is classified into polymerase chain reaction (PCR) and next-generation sequencing (NGS).
In terms of indication segment, the global market has been categorized into breast cancer, lung cancer, colorectal cancer, gastric cancer, melanoma, and others. Based on end-user, the market is classified into pharmaceutical & biopharmaceutical companies, laboratories, contract research organizations, and others.
Regional Analysis
Geographically, the Global Companion Diagnostics for Oncology Market is classified into four main regions, namely the Americas, Europe, Asia-Pacific, and the Middle East & Africa.
The Americas is likely to drive the largest market owing to the major share in 2019 and it is expected to command the market during the forecast period. The regional market is attributed to the high prevalence rate of cancer and other chronic disorders and growing healthcare expenditure.
Europe is expected to register the second-largest market share owing to the existence of many companies, rising research and development activities to develop targeted drug therapy for a cancer patient, and rising per capita income increases the preference for personalized medicine.
Asia-Pacific is anticipated to be the fastest-growing regional market during the review period owing to the increasing number of cancer patients and the growing presence of market players. Furthermore, the increasing research funding, increasing investments by pharmaceutical and biotechnology companies, and rising awareness about personalized therapeutics in several APAC countries are expected to propel the growth of the Asia-Pacific market.
The Middle East & Africa is expected to register a steady market growth during the review period owing to the emerging market in countries such as Kuwait, the UAE, and Saudi Arabia.
Major Players
The Key Players in the Global Companion Diagnostics for Oncology Market include Agilent Technologies Inc., Illumina, Inc., F. Hoffmann-La Roche Ltd, BioMérieux SA, Foundation Medicine, Archer Dx, Qiagen, Thermo Fisher Scientific Inc., Amoy Dx, and Abbott.
COVID 19 Impacts
We are continuously tracking the impact of the COVID-19 pandemic on various industries and verticals within all domains. Our research reports include the same and help you understand the drop and rise, owing to the impact of COVID-19 on the industries. Also, we help you to identify the gap between the demand and supply of your interested market. Moreover, the report helps you with the analysis, amended government regulations, and many other useful insights.

Global Radiation Therapy in the Oncology Market: Focus on Radiation Therapy Systems, Product Regulation, Key Strategies and Developments, Market Dynamics, 15 Company Profiles, and 12 Countries Data and Cross Segmentation – Analysis and Forecast, 2021-2031

Additional information

Publisher

Geography Covered

Date Published

Pages

Format

Table of Contents

TABLE OF CONTENT 1 EXECUTIVE SUMMARY

1.1 MARKET SYNOPSIS 16

1.2 MARKET ATTRACTIVENESS ANALYSIS 17

2 MARKET INTRODUCTION

2.1 DEFINITION 18

2.2 SCOPE OF THE STUDY 18

2.3 RESEARCH OBJECTIVE 18

2.4 MARKET STRUCTURE 18

2.5 ASSUMPTIONS & LIMITATIONS 19

3 RESEARCH METHODOLOGY

3.1 DATA MINING 20

3.2 SECONDARY RESEARCH 21

3.3 PRIMARY RESEARCH 22

3.4 BREAKDOWN OF PRIMARY RESPONDENTS 23

3.5 FORECASTING TECHNIQUES 24

3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION 25

3.6.1 BOTTOM-UP APPROACH 26

3.6.2 TOP-DOWN APPROACH 26

3.7 DATA TRIANGULATION 27

3.8 VALIDATION 27

4 MARKET DYNAMICS

4.1 OVERVIEW 28

4.2 DRIVERS 29

4.2.1 RISING PREFERENCE OF PERSONALIZED MEDICINE 29

4.2.2 INCREASING PRODUCT APPROVAL BY MAJOR PLAYERS 29

4.2.3 INCREASING COLLABORATION AMONG COMPANIES AND DRUG-DIAGNOSTIC CO-DEVELOPMENT 30

4.2.4 INCREASING GLOBAL INCIDENCE OF CANCER 30

4.3 RESTRAINTS 31

4.3.1 LACK OF REIMBURSEMENT IN DEVELOPING REGIONS 31

4.4 OPPORTUNITIES 32

4.4.1 ENTRY OF MARKET PLAYERS INTO EMERGING ECONOMIES 32

5 MARKET FACTOR ANALYSIS

5.1 PORTER’S FIVE FORCES MODEL 33

5.1.1 THREAT OF NEW ENTRANTS 33

5.1.2 BARGAINING POWER OF SUPPLIERS 34

5.1.3 THREAT OF SUBSTITUTES 34

5.1.4 BARGAINING POWER OF BUYERS 34

5.1.5 INTENSITY OF RIVALRY 34

5.2 SUPPLY CHAIN ANALYSIS 35

5.2.1 R&D AND DESIGNING 36

5.2.2 MANUFACTURING 36

5.2.3 DISTRIBUTION 36

5.2.4 MARKETING & SALES 36

5.2.5 POST-SALES MONITORING 36

5.3 IMPACT OF COVID-19 ON THE GLOBAL COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET 36

5.3.1 OVERVIEW 36

5.3.2 IMPACT ON SUPPLY CHAIN 37

5.3.3 IMPACT ON PRODUCTION 37

5.3.4 IMPACT ON KEY PLAYERS 37

5.3.5 IMPACT ON REGIONS 37

6 GLOBAL COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY PRODUCTS & SERVICES

6.1 OVERVIEW 38

6.2 ASSAYS, KITS & REAGENTS 39

6.3 SOFTWARE & SERVICES 40

7 GLOBAL COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY TECHNOLOGY

7.1 OVERVIEW 41

7.2 POLYMERASE CHAIN REACTION (PCR) 42

7.3 NEXT-GENERATION SEQUENCING (NGS) 43

8 GLOBAL COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY INDICATION

8.1 OVERVIEW 44

8.2 LUNG CANCER 46

8.3 BREAST CANCER 46

8.4 COLORECTAL CANCER 47

8.5 GASTRIC CANCER 47

8.6 MELANOMA 48

9 GLOBAL COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY END USER

9.1 OVERVIEW 49

9.2 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES 51

9.3 CONTRACT RESEARCH ORGANIZATIONS 51

9.4 LABORATORIES 52

10 GLOBAL COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY REGION

10.1 OVERVIEW 53

10.2 AMERICAS 55

10.2.1 NORTH AMERICA 57

10.2.1.1 US 59

10.2.1.2 CANADA 60

10.2.2 LATIN AMERICA 62

10.3 EUROPE 64

10.3.1 WESTERN EUROPE 66

10.3.1.1 GERMANY 68

10.3.1.2 UK 70

10.3.1.3 FRANCE 71

10.3.1.4 ITALY 72

10.3.1.5 SPAIN 74

10.3.1.6 REST OF WESTERN EUROPE 75

10.3.2 EASTERN EUROPE 77

10.4 ASIA-PACIFIC 79

10.4.1 CHINA 81

10.4.2 JAPAN 82

10.4.3 INDIA 84

10.4.4 AUSTRALIA 85

10.4.5 SOUTH KOREA 87

10.4.6 REST OF ASIA-PACIFIC 88

10.5 MIDDLE EAST & AFRICA 90

10.5.1 MIDDLE EAST 92

10.5.2 AFRICA 93

11 COMPETITIVE LANDSCAPE

11.1 OVERVIEW 95

11.2 COMPETITIVE BENCHMARKING 96

11.3 GLOBAL COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET: COMPANY RANKING 97

11.4 MAJOR GROWTH STRATEGY IN THE GLOBAL COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET 98

11.5 LEADING PLAYERS IN TERMS OF NUMBER OF DEVELOPMENTS 98

11.6 KEY DEVELOPMENTS & GROWTH STRATEGIES 99

11.6.1 PRODUCT APPROVALS AND LAUNCHES 99

11.6.2 JOINT VENTURES 102

11.6.3 EXPANSIONS 105

11.6.4 ACQUISITIONS 105

11.7 FINANCIAL MATRIX 106

12 COMPANY PROFILES

12.1 F. HOFFMANN-LA ROCHE LTD 107

12.1.1 COMPANY OVERVIEW 107

12.1.2 FINANCIAL OVERVIEW 108

12.1.3 PRODUCTS/SERVICES OFFERED 108

12.1.4 KEY DEVELOPMENTS 109

12.1.5 SWOT ANALYSIS 110

12.1.6 KEY STRATEGIES 110

12.2 THERMO FISHER SCIENTIFIC INC. 111

12.2.1 COMPANY OVERVIEW 111

12.2.2 FINANCIAL OVERVIEW 111

12.2.3 PRODUCTS/SERVICES OFFERED 112

12.2.4 KEY DEVELOPMENTS 112

12.2.5 SWOT ANALYSIS 113

12.2.6 KEY STRATEGIES 113

12.3 QIAGEN 114

12.3.1 COMPANY OVERVIEW 114

12.3.2 FINANCIAL OVERVIEW 114

12.3.3 PRODUCTS/SERVICES OFFERED 115

12.3.4 KEY DEVELOPMENTS 115

12.3.5 SWOT ANALYSIS 117

12.3.6 KEY STRATEGIES 117

12.4 BIOMÉRIEUX SA 118

12.4.1 COMPANY OVERVIEW 118

12.4.2 FINANCIAL OVERVIEW 118

12.4.3 PRODUCTS/SERVICES OFFERED 119

12.4.4 KEY DEVELOPMENTS 119

12.4.5 SWOT ANALYSIS 119

12.4.6 KEY STRATEGIES 119

12.5 ILLUMINA, INC. 120

12.5.1 COMPANY OVERVIEW 120

12.5.2 FINANCIAL OVERVIEW 120

12.5.3 PRODUCTS/SERVICES OFFERED 121

12.5.4 KEY DEVELOPMENTS 121

12.5.5 SWOT ANALYSIS 122

12.5.6 KEY STRATEGIES 122

12.6 ARCHERDX, INC. 123

12.6.1 COMPANY OVERVIEW 123

12.6.2 FINANCIAL OVERVIEW 123

12.6.3 PRODUCTS/SERVICES OFFERED 123

12.6.4 KEY DEVELOPMENTS 124

12.6.5 SWOT ANALYSIS 125

12.6.6 KEY STRATEGIES 125

12.7 FOUNDATION MEDICINE, INC. 126

12.7.1 COMPANY OVERVIEW 126

12.7.2 FINANCIAL OVERVIEW 126

12.7.3 PRODUCTS/SERVICES OFFERED 126

12.7.4 KEY DEVELOPMENTS 127

12.7.5 SWOT ANALYSIS 128

12.7.6 KEY STRATEGIES 128

12.8 AMOY DIAGNOSTICS CO. LTD 129

12.8.1 COMPANY OVERVIEW 129

12.8.2 FINANCIAL OVERVIEW 129

12.8.3 PRODUCTS/SERVICES OFFERED 129

12.8.4 KEY DEVELOPMENTS 130

12.8.5 SWOT ANALYSIS 131

12.8.6 KEY STRATEGIES 131

12.9 AGILENT TECHNOLOGIES, INC. 132

12.9.1 COMPANY OVERVIEW 132

12.9.2 FINANCIAL OVERVIEW 132

12.9.3 PRODUCTS/SERVICES OFFERED 133

12.9.4 KEY DEVELOPMENTS 133

12.9.5 SWOT ANALYSIS 134

12.9.6 KEY STRATEGIES 134

12.10 ABBOTT 135

12.10.1 COMPANY OVERVIEW 135

12.10.2 FINANCIAL OVERVIEW 135

12.10.3 PRODUCTS/SERVICES OFFERED 136

12.10.4 KEY DEVELOPMENTS 136

12.10.5 SWOT ANALYSIS 136

12.10.6 KEY STRATEGIES 137

13 APPENDIX

13.1 REFERENCES 138

13.2 RELATED REPORTS 138